Ignite Creation Date:
2024-05-06 @ 12:34 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03797326
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-31
First Post:
2019-01-07
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 Plus Lenvatinib E7080MK-7902 in Previously Treated Participants With Select Solid Tumors MK-7902-005E7080-G000-224LEAP-005
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pancreatic Cancer |
| Advanced Solid Tumors |
| Triple Negative Breast Cancer |
| Ovarian Cancer |
| Gastric Cancer |
| Colorectal Cancer |
| Glioblastoma |
| Biliary Tract Cancers |
Keywords:
| Name | View |
|---|---|
| Platelet-Derived Growth Factor PDGF | View |
| programmed cell death 1 PD-1 PD1 | View |
| programmed cell death ligand 1 PD-L1 PDL1 | View |
| programmed cell death ligand 2 PD-L2 PDL2 | View |
| tyrosine kinase inhibitor TKI | View |
| multiple TKI | View |
| Vascular Endothelial Growth Factor Receptor VEFG | View |
| Fibroblast Growth Factor FGF | View |